Form 4: CEO Hall Boosts Personalis Stake with New Equity Awards

Personalis CEO Christopher M. Hall received 87,500 restricted stock units and 525,000 stock options, increasing his beneficial ownership.

Summary

• Christopher M. Hall, CEO and Director of Personalis, Inc., acquired 87,500 shares of common stock in the form of Restricted Stock Units (RSUs) on March 15, 2026.
• He also acquired 525,000 stock options with an exercise price of $6.72 per share on March 15, 2026.
• The RSUs vest in 6 equal semi-annual installments, with the first vesting on September 15, 2026.
• The stock options vest in 36 equal monthly installments, with the first vesting on April 15, 2026, and expire on March 15, 2036.
• Following these transactions, Hall beneficially owns 235,986 shares of common stock and 525,000 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates management's continued commitment and alignment with shareholder interests through significant equity awards, though it's a routine compensation event.

Positives

• CEO Christopher M. Hall received significant equity awards (87,500 RSUs and 525,000 stock options), aligning his interests with shareholders.
• The acquisition of these awards at a $0 price for RSUs and an exercise price of $6.72 for options indicates performance-based or incentive compensation.

Risks

• The value of the equity awards is subject to the future performance of Personalis, Inc.'s stock price.
• Vesting schedules mean the full benefit of these awards is not immediate and depends on continued employment and company performance.

Future Outlook

The equity awards granted to CEO Christopher M. Hall are structured with vesting schedules extending into 2026 and beyond, indicating a long-term incentive for management tied to future company performance.

Industry Context

StockSavvy.ai notes that equity awards, such as RSUs and stock options, are standard components of executive compensation packages across various industries, particularly in growth-oriented sectors like biotechnology or healthcare technology where Personalis, Inc. operates. These awards are designed to align executive incentives with long-term shareholder value creation, a common practice among peers.

Comparison to Industry Standards

• The grant of significant equity awards to a CEO is a common practice in publicly traded companies, especially in the biotechnology and genomics sectors, to incentivize long-term performance and retention.
• Vesting schedules, such as the 6 semi-annual installments for RSUs and 36 monthly installments for options, are typical mechanisms to ensure sustained commitment and performance over several years, comparable to practices at companies like Illumina or Guardant Health.
• The exercise price of $6.72 for options is set at the market price on the grant date, which is standard for incentive stock options, aligning with best practices for executive compensation.

Related Party Transactions

• The transaction involves the CEO and the company, which is a standard compensation event reported on Form 4.

Stakeholder Impact

• Shareholders: The equity awards align the CEO's long-term interests with shareholders, potentially motivating performance that drives stock value.
• Employees: May signal stability in leadership and a commitment to long-term growth.

Next Steps

• The RSUs will begin vesting on September 15, 2026, in 6 equal semi-annual installments.
• The stock options will begin vesting on April 15, 2026, in 36 equal monthly installments.

Key Dates

Keywords

Personalis, PSNL, Christopher M. Hall, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Equity Awards, CEO Compensation